Strainprint™ Closes USD $3 Million (Cdn.$3.8M) Series A Funding

TORONTOMay 8, 2018 /PRNewswire/ – StrainprintTM Technologies — the leader in cannabis data and analytics is pleased to announce the closing of a USD $3 Million (Cdn.$3.8 Million) non-brokered, Series A private placement. The round was led by strategic industry investor, Cesare Fazari, Chairman of Molecular Science Corp and seed investor of leading cannabis companies, Ample Organics and Hydropothecary. Mr. Fazari will also join Strainprint’s Board of Directors and will play an active role in strategic business development.  The round also includes a significant follow-on investment from NY-based, Core Strain Ltd., as well as participation from a number of Toronto-based capital funds.

Strainprint will use proceeds for talent acquisition and to rapidly expand sales and marketing of its disruptive Strainprint Analytics web platform across North America and into key international markets like Australia and Germany. The company will also continue to innovate its industry-leading outcomes-tracking mobile journal for patients with symptom-specific measurement protocols and ethics compliance, developed together with our world-class medical advisors.

Since February 2017, tens of thousands of medical cannabis patients have tracked over 500,000 medical records on Strainprint’s mobile patient journal, generating over 7 million data points on strain efficacy and patient use.  It is the largest and most granular longitudinal study of its kind and its growing by 25% per month. In addition to helping patients lead healthier lives, this medically validated data is helping to shape the entire cannabis industry by providing business intelligence, as well as treatment and product guidance for producers, retailers, clinicians, researchers, pharma, insurance and government.

“This funding round represents a key milestone for Strainprint that will allow us to capitalize on our first-mover advantage as the premier source of medical cannabis use data,” said Strainprint CEO, Andrew Muroff. “Amongst other initiatives, we plan to rapidly provision our team and SaaS products to serve international markets where imported Canadian cannabis is the primary source of available product.”

The Strainprint mobile app is available for free to patients on both iOS and Android, while web-based Strainprint Analytics is available by monthly subscription.

About StrainprintTM:
Founded in Toronto in 2016,StrainprintTM Technologies Ltd. is the leading demand-side cannabis data and analytics company, gathering real-time cannabis consumption and efficacy data on lab-verified strains, while providing enterprise business intelligence to the global cannabis industry. StrainprintTM data supports global cannabis research and provides advanced business intelligence to producers, retailers, medical practitioners, pharma, government and industry. Strainprint is HIPAA, PIPEDA and PHIPA privacy compliant, military-grade encrypted and all patient data is anonymized and at rest in Canada. Strainprint can be seamlessly embedded or integrated with most electronic medical records (EMR), seed2sale and Ecomm software systems.  The Strainprint App is free to patients and can be downloaded from both the iOS App and GooglePlay stores. www.strainprintanalytics.comwww.strainprint.cafacebooktwitterlinkedin

Strainprint™ Technologies Ltd. Welcomes 48North Cannabis Co. parent company of ACMPR Licensed Producer Delshen Therapeutics

TORONTO, Dec. 21, 2017 /CNW/ – Strainprint™ – the leader in cannabis data collection and strain efficacy reporting – is excited to announce that 48North Cannabis (48North) has subscribed to Strainprint’s world-leading cannabis data & analytics platform to help guide its operational growth and product development.

48North’s Ontario-based cultivation facility Delshen Therapeutics is a Health Canada Licensed Producer with unique genetics sourced from the Netherlands’ first cannabis license holder, MariPharm B.V. 48 North plans to use Strainprint’s data and analytics tools to support the existing medical research on their proprietary strains and to develop cannabis products and brands that meet the needs of a variety of consumers.

“Strainprint’s unique ACMPR strain efficacy and patient use data will help us to produce the highest quality products that will support our patients and recreational consumers in navigating their cannabis experiences.,” said Alison Gordon, 48North CEO.

Thousands of ACMPR patients have tracked almost 150,000 medication sessions from our industry-leading mobile app generating over 4 million data points on strain efficacy and patient use.  It is the largest and most granular longitudinal data set in the world on strain efficacy and patient use of lab-verified products.  In addition to guiding patients, this data is helping to shape the entire cannabis industry by providing business intelligence for all stakeholders, including licensed producers, doctors and clinics, researchers, pharma and insurance providers.

“Our mission is to help our users and our subscriber customers to better understand how cannabis works and how it can best be used for whatever their purpose.  We are ecstatic to be working with 48North to provide them with the most reliable source of data that will be instrumental for developing premium products for their consumers and patients,” said Strainprint CEO, Andrew Muroff.

The Strainprint mobile App is free and is available for both iOS & Android from the Apple iTunes and Google Play Stores, respectively.

About Strainprint™

Founded in Toronto in 2016, Strainprint™ Technologies Ltd. is the leading demand-side cannabis data and analytics company, gathering real-time cannabis consumption and efficacy data on lab-verified strains, while providing enterprise business intelligence to the global cannabis industry. Strainprint™ data supports global cannabis research and provides advanced business intelligence to producers, retailers, medical practitioners, pharma, government and industry. Strainprint is HIPAA, PIPEDA and PHIPA privacy compliant, military-grade encrypted and all patient data is completely anonymized and at rest in Canada. Strainprint can be seamlessly embedded or integrated with most electronic medical records (EMR) and seed2sale software systems. The Strainprint App is free to patients and can be downloaded from both the iOS App Store and GooglePlay Store. For more information visit www.strainprint.ca, facebook, twitter, linkedin

About 48 North

48North is a vertically integrated cannabis company. Its first ACMPR licensed facility is located on 800 acres of owned land near Kirkland Lake, Ontario, and is operated by its wholly-owned subsidiary, DelShen Therapeutics. The company grows unique genetics sourced from MariPharm B.V., a Netherlands based phytopharmaceutical company with over 25 years of experience in the research and cultivation of cannabis for medical purposes. The genetics are grown to exacting standards in DelShen’s state-of-the-art, closed box facility, ensuring patients can count on receiving the highest quality cannabis products. 48North’s values are rooted in the land they’re planted on, and the company has entered into a first of its kind Community Benefits Agreement with certain of its First Nations investors.

SOURCE Strainprint™ Technologies Ltd.

Media Contact

Jessica Moran
519-494-5379
Strainprint Technologies Ltd.
jessica.moran@strainprint.ca

Strainprint™ Technologies Ltd. Launches Custom-Branded OEM Version of Industry-Leading Mobile Cannabis Journaling App for Canna Farms

TORONTO, Nov. 21, 2017 /CNW/ – Strainprint™ — the leader in cannabis data collection and strain efficacy reporting — is pleased to announce the release of the Canna Farms OEM version of the Strainprint mobile App. The newest custom-branded version of the Strainprint App is available exclusively for Canna Farms customers through a unique activation code.

Canna Farms is a Health Canada Licensed Producer (“LP”) of craft cannabis products, and the first ACMPR LP in British Columbia. “We are very excited about having this branded version of the Strainprint App as it will create an easy and efficient way for our customers to track their cannabis usage and determine what strains work best for them,” said Canna Farms’ President, Ray Laflamme.

In addition to helping build the Canna Farms community, the exclusive version of the App sets Canna Farms apart from other LPs. “We’re thrilled to be working with the Canna Farms team. They truly understand the value of incorporating technology to better communicate with their customers and expand their reach while using Strainprint as a key component,” said Evan Karasick, Strainprint’s Chief Product Officer.

Strainprint offers custom-branded versions of its mobile App for producers, clinics, researchers and industry. This enables rapid community development through prompted messaging and configurable loyalty engagement in compliance with Health Canada regulations.

The Strainprint mobile App is free and is available for both iOS & Android from the Apple iTunes and Google Play Stores, respectively. Canna Farms’ customers will receive a unique code to activate the additional features.

About Strainprint™

Founded in Toronto in 2016, StrainprintTM Technologies Ltd. is the leading demand-side cannabis data and analytics company, gathering real-time cannabis consumption and efficacy data on lab-verified strains, while providing enterprise business intelligence to the global cannabis industry. StrainprintTM data supports global cannabis research and provides advanced business intelligence to producers, retailers, medical practitioners, pharma, government and industry. Strainprint is HIPAA, PIPEDA and PHIPA privacy compliant, military-grade encrypted and all patient data is completely anonymized and at rest in Canada. Strainprint can be seamlessly embedded or integrated with most electronic medical records (EMR) and seed2sale software systems. The Strainprint App can be downloaded from both the iOS App Store and GooglePlay Store. For more information visit www.strainprint.ca.

About Canna Farms

Canna Farms is a Health Canada Licensed Producer of craft cannabis products and was the first ACMPR Licensed Producer in British Columbia. Their team is dedicated to providing patients with exceptional cannabis products at an affordable price.

Canna Farms, 1-855-882-0988, www.cannafarms.ca

SOURCE Strainprint™ Technologies Ltd.

Media Contact

Jessica Moran
Strainprint™ Technologies Ltd
jessica.moran@strainprint.ca
(519) 494-5379

Strainprint™ Technologies Ltd. (“Strainprint”) Opens its Ambassador Program With Denver-based IMPACT Network

 

Strainprint, leader in cannabis data collection and strain efficacy reporting.

TORONTOAug. 23, 2017 /CNW/ – Strainprint™, the leader in cannabis data collection and strain efficacy reporting, is pleased to announce the launch of its Ambassador Research Program. The Strainprint Ambassador program is available to qualified researchers that use Strainprint’s revolutionary data gathering and analytics tools to conduct observational cannabis studies in relation to specific medical conditions.

“From inception, Strainprint was developed with research in mind.  The Ambassador program is just one more way that we are working to advance the study and use of cannabis as a legitimate therapeutic for a variety of symptoms and conditions,” said Dave Berg, Strainprint Chief Technology Officer.

Ambassador researchers get a study-specific version of the Strainprint mobile app for their patients and get subsidized access to their segregated, confidential patient data-set through Strainprint’s upcoming web-based clinical interface and analytics platform.  In exchange, Strainprint receives a credit as the key data collection and analytics tool on any published Ambassador research and all anonymized data becomes part of the Strainprint community.  Strainprint will also begin to feature Ambassadors as guest Bloggers in key medical cannabis education.

One of the first Strainprint Ambassadors is IMPACT Network, http://www.impactcannabis.org, a Denver-based 501c3 nonprofit research institute registered with the U.S. National Institute of Health.  IMPACT Network’s WMEDS study will be the first longitudinal study of cannabis for women’s health.  “Our mission is to Improve marijuana policy and accelerate cannabinoid therapeutics for women worldwide. The Strainprint app is the best tool we’ve found for our research and reporting needs,” said Dr. Michele Ross, Founder & Executive Director of IMPACT Network.

The Strainprint App can be downloaded from both the iOS App Store and GooglePlay Store.

About Strainprint™

Founded in Toronto in 2016, Strainprint™ Technologies Ltd. is a Toronto-based software company providing enterprise grade analytics and consumer solutions for the medical cannabis industry. Strainprint manages the gathering and analysis of real-time cannabis consumption data and ranks specific strain efficacy against conditions and related symptoms. Strainprint™ data supports cannabis researchers globally and provides advanced intelligence to licensed producers to optimize grow operations and to clinics to improve treatment recommendations. For more information visit www.strainprint.cafacebooktwitterlinkedin

SOURCE Strainprint Technologies Ltd. 

Media Contact

Jessica Moran
519-494-5379
Strainprint Technologies Ltd.
jessica.moran@strainprint.ca